Primary Care Issues in Patients with Mental Illness



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Family physicians commonly care for patients with serious mental illness. Patients with psychotic and bipolar disorders have more comorbid medical conditions and higher mortality rates than patients without serious mental illness. Many medications prescribed for serious mental illness have significant metabolic and cardiovascular adverse effects. Patients treated with second-generation antipsychotics should receive preventive counseling and treatment for obesity, hyperglycemia, diabetes, and hyperlipidemia. First- and second-generation antipsychotics have been associated with QT prolongation. Many common medications can interact with antipsychotics, increasing the risk of cardiac arrhythmias and sudden death. Drug interactions can also lead to increased adverse effects, increased or decreased drug levels, toxicity, or treatment failure. Physicians should carefully consider the risks and benefits of second-generation antipsychotic medications, and patient care should be coordinated between primary care physicians and mental health professionals to prevent serious adverse effects.

Serious mental illness (i.e., schizophrenia, nonaffective psychotic disorders, bipolar spectrum disorders, substance dependence, and suicidality) affects 6 percent of adults in the United States.1 Patients with these disorders have a higher risk of mortality associated with clinical disease and unnatural causes (e.g., suicide, homicide, accidents).2,3 Common medical conditions in patients with serious mental illness include metabolic disorders, cardiovascular disease, chronic pulmonary disease, gastrointestinal disorders, and obesity.4,5

Historically, efforts to improve the health of patients with mental illness focused solely on pharmacologic treatment. However, recent efforts have also included medical comorbidities and quality of medical care.6,7

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Patients using second-generation antipsychotics should receive counseling to prevent obesity, hyperlipidemia, and diabetes.*

C

24

When possible, primary care physicians should avoid prescribing drugs that interact with psychiatric medications in patients with serious mental illness.

C

19, 3335

To avoid medication-related adverse outcomes, primary care physicians and mental health professionals should coordinate the care of patients with serious mental illness.

C

47


*— Recommendation from consensus guidelines of the American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Patients using second-generation antipsychotics should receive counseling to prevent obesity, hyperlipidemia, and diabetes.*

C

24

When possible, primary care physicians should avoid prescribing drugs that interact with psychiatric medications in patients with serious mental illness.

C

19, 3335

To avoid medication-related adverse outcomes, primary care physicians and mental health professionals should coordinate the care of patients with serious mental illness.

C

47


*— Recommendation from consensus guidelines of the American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see http://www.aafp.org/afpsort.xml.

Causes of Poor Health

Several factors contribute to poor health and increased mortality in patients with serious mental illness. These patients may have decreased access to health insurance and medical care and may delay seeking care because of cost.8 One study showed that persons with mental illness were less likely to receive preventive care, including cancer screening, tobacco-use counseling, and immunizations.6 Patients with mental illness are also less likely to receive appropriate treatment for acute problems, such as coronary revascularization procedures following an acute myocardial infarction.9

A study that surveyed family physicians about patients with common complaints (severe headache or abdominal pain) and comorbid mental illness showed that physicians underestimate the pretest probability of disease and, consequently, obtain fewer appropriate tests.10 Patients with mental illness who have been diagnosed with diabetes and hyperlipidemia are only 29 percent as likely to be prescribed a statin medication as patients without mental health problems.11 Patients with mental illness report poor coordination of care between primary care physicians and mental health professionals.12 Lifestyle and behavioral factors also contribute to increased comorbidities in these patients. Patients with schizophrenia in particular have poorer dietary habits, smoke more, and exercise less than the general population.13,14

Medication adverse effects and interactions contribute to medical comorbidities. Primary care physicians and mental health professionals may not be aware of each medication these patients have been prescribed, increasing the risk of interactions. Many common psychiatric medications (Table 1) cause serious adverse effects. First-generation antipsychotics cause extrapyramidal adverse effects, including tardive dyskinesia, whereas second-generation antipsychotics may cause metabolic adverse effects, including weight gain, obesity, glucose intolerance, diabetes, and hyperlipidemia. Both antipsychotic classes are associated with cardiovascular adverse effects, particularly QT prolongation.

Table 1

Common Antipsychotic Medications

First-generation antipsychotics*

Chlorpromazine (Thorazine†)

Fluphenazine (Prolixin†)

Haloperidol (Haldol)

Loxapine (Loxitane)

Mesoridazine (Serentil); this medication has been discontinued in the United States

Molindone (Moban)

Perphenazine (Trilafon†)

Pimozide (Orap)

Prochlorperazine (Compro)

Thioridazine (Mellaril†)

Thiothixene (Navane)

Trifluoperazine (Stelazine†)

Second-generation antipsychotics

Aripiprazole (Abilify)

Clozapine (Clozaril)

Olanzapine (Zyprexa)

Paliperidone (Invega)

Quetiapine (Seroquel)

Risperidone (Risperdal)

Ziprasidone (Geodon)


*— Also called typical antipsychotics; associated with an increased incidence of extra-pyramidal symptoms and increased cognitive impairment.

†— Brand no longer available in the United States.

‡— Also called atypical antipsychotics; associated with a decreased incidence of extra-pyramidal symptoms.

Table 1   Common Antipsychotic Medications

View Table

Table 1

Common Antipsychotic Medications

First-generation antipsychotics*

Chlorpromazine (Thorazine†)

Fluphenazine (Prolixin†)

Haloperidol (Haldol)

Loxapine (Loxitane)

Mesoridazine (Serentil); this medication has been discontinued in the United States

Molindone (Moban)

Perphenazine (Trilafon†)

Pimozide (Orap)

Prochlorperazine (Compro)

Thioridazine (Mellaril†)

Thiothixene (Navane)

Trifluoperazine (Stelazine†)

Second-generation antipsychotics

Aripiprazole (Abilify)

Clozapine (Clozaril)

Olanzapine (Zyprexa)

Paliperidone (Invega)

Quetiapine (Seroquel)

Risperidone (Risperdal)

Ziprasidone (Geodon)


*— Also called typical antipsychotics; associated with an increased incidence of extra-pyramidal symptoms and increased cognitive impairment.

†— Brand no longer available in the United States.

‡— Also called atypical antipsychotics; associated with a decreased incidence of extra-pyramidal symptoms.

OBESITY AND WEIGHT GAIN

Obesity associated with serious mental illness is multifactorial.5 Medication effects, poor nutrition, difficulty with meal planning, poor impulse control, and lack of exercise contribute to weight gain.15  Second-generation antipsychotics can cause rapid weight gain in the first few months of therapy (Table 21619), and it can take up to one year for body weight to stabilize. Average weight gain varies from 1 lb, 2 oz (0.5 kg) to 11 lb (5.0 kg) within the first 10 weeks of therapy. The mechanism of antipsychotic-induced weight gain is unknown.

Table 2

Selected Antipsychotics Associated with Weight Gain

Medication Effect on weight gain

First-generation antipsychotics

Weight gain is generally less than with second-generation antipsychotics, but the effects are widely variable

Second-generation antipsychotics*

Aripiprazole (Abilify)

Similar to placebo16

Clozapine (Clozaril)

Average weight gain at 10 weeks: 9 lb, 13 oz (4.45 kg)17,18

Olanzapine (Zyprexa)

Average weight gain at 10 weeks: 9 lb, 2 oz (4.15 kg)17,18

Quetiapine (Seroquel)

Weight gain ranges from minimal to a mean gain of 5 lb, 8 oz (2.49 kg) at six weeks17

Risperidone (Risperdal)

Average weight gain at 10 weeks: 4 lb, 10 oz (2.10 kg)17,18

Ziprasidone (Geodon)

Average weight gain at 10 weeks: 1 oz (0.04 kg)18


*— Combining second-generation antipsychotics with mood stabilizers, particularly lithium and valproate (Depacon), leads to additional weight gain.19

Information from references 16 through 19.

Table 2   Selected Antipsychotics Associated with Weight Gain

View Table

Table 2

Selected Antipsychotics Associated with Weight Gain

Medication Effect on weight gain

First-generation antipsychotics

Weight gain is generally less than with second-generation antipsychotics, but the effects are widely variable

Second-generation antipsychotics*

Aripiprazole (Abilify)

Similar to placebo16

Clozapine (Clozaril)

Average weight gain at 10 weeks: 9 lb, 13 oz (4.45 kg)17,18

Olanzapine (Zyprexa)

Average weight gain at 10 weeks: 9 lb, 2 oz (4.15 kg)17,18

Quetiapine (Seroquel)

Weight gain ranges from minimal to a mean gain of 5 lb, 8 oz (2.49 kg) at six weeks17

Risperidone (Risperdal)

Average weight gain at 10 weeks: 4 lb, 10 oz (2.10 kg)17,18

Ziprasidone (Geodon)

Average weight gain at 10 weeks: 1 oz (0.04 kg)18


*— Combining second-generation antipsychotics with mood stabilizers, particularly lithium and valproate (Depacon), leads to additional weight gain.19

Information from references 16 through 19.

DIABETES

Before the availability of antipsychotic medications, the prevalence of diabetes in patients with schizophrenia was estimated at 2.5 to 4.2 percent.20 A recent cross-sectional study of patients in Holland with schizophrenia and schizoaffective disorder, showed that the prevalence of hyperglycemia and diabetes are 7.0 and 14.5 percent, respectively.21

The increased risk of type 2 diabetes in patients with schizophrenia or bipolar disorder is associated with the increased use of second-generation antipsychotics.22,23 Although the exact mechanism for hyperglycemia is unknown, it may be caused by drug-induced insulin resistance from associated weight gain, changes in body fat distribution, or direct effects on insulin-sensitive target tissues.24

New-onset diabetes, worsening of known diabetes, and hyperglycemic crises have been reported after the initiation of second-generation antipsychotics. The U.S. Food and Drug Administration requires that labels for all second-generation antipsychotics include warnings about the risk of hyperglycemia and diabetes. Clozapine (Clozaril) and olanzapine (Zyprexa) are associated with the greatest risk. Clinical trials of ziprasidone (Geodon) and aripiprazole (Abilify) lasting up to one year demonstrated rates of weight gain and metabolic changes similar to that of placebo.25

HYPERLIPIDEMIA

Second-generation antipsychotics are associated with increased serum triglyceride and total cholesterol levels. Clozapine appears to have the strongest effect, increasing triglyceride levels by up to 42 percent. Olanzapine has been associated with a 38 percent increase in triglyceride levels and a 10 percent decrease in high-density lipoprotein (HDL) cholesterol levels, with the maximal effect occurring within 10 months of initiating therapy. Quetiapine (Seroquel) increases triglyceride levels by 17 percent and may decrease HDL cholesterol levels. Risperidone's (Risperdal) effect on lipid levels is unclear.26 Aripiprazole and ziprasidone have not been shown to have significant effects on lipid levels.26 There is no conclusive evidence that these changes in lipid profiles lead to increased cardiovascular events.27

Guidelines for the Prevention and Treatment of Metabolic Changes

The American Diabetes Association (ADA), American Psychiatric Association (APA), American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity convened a consensus panel in November 2003 to develop guidelines for the prevention and treatment of metabolic changes induced by antipsychotic therapy.24  The following section summarizes the panel's recommendations on lifestyle counseling, obesity management, patient education, and treatment goals. The recommended monitoring protocol for patients receiving second-generation antipsychotics is summarized in Table 3.24

Table 3

Monitoring Recommendations for Patients Receiving Second-Generation Antipsychotics

Assessment Frequency of assessment
Baseline Four weeks Eight weeks 12 weeks Quarterly Annually Every five years

Review personal and family history

X

X

Weight (body mass index)

X

X

X

X

X

Waist circumference

X

X

Blood pressure

X

X

X

Fasting plasma glucose level

X

X

X

Fasting lipid profile

X

X

X


note: Table reflects the minimum frequency of assessments; more frequent monitoring may be appropriate in select patients based on underlying conditions and family history.

Adapted with permission from American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):599.

Table 3   Monitoring Recommendations for Patients Receiving Second-Generation Antipsychotics

View Table

Table 3

Monitoring Recommendations for Patients Receiving Second-Generation Antipsychotics

Assessment Frequency of assessment
Baseline Four weeks Eight weeks 12 weeks Quarterly Annually Every five years

Review personal and family history

X

X

Weight (body mass index)

X

X

X

X

X

Waist circumference

X

X

Blood pressure

X

X

X

Fasting plasma glucose level

X

X

X

Fasting lipid profile

X

X

X


note: Table reflects the minimum frequency of assessments; more frequent monitoring may be appropriate in select patients based on underlying conditions and family history.

Adapted with permission from American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):599.

EXERCISE AND WEIGHT MANAGEMENT

Patients with serious mental illness are more likely to be physically inactive than the general population. Factors associated with physical inactivity include female sex and limited social contacts.13 All patients with mental illness treated with second-generation antipsychotics should receive physical activity counseling, and those who are overweight or obese should also receive nutrition counseling.

If a patient's weight increases by more than 5 percent, physicians should consider changing, using slow cross-titration, to another second-generation antipsychotic that is not associated with weight gain.24 If possible, patients should be referred to a weight management program specifically tailored to patients with serious mental illness.

DRUG SELECTION

When prescribing a second-generation anti-psychotic, physicians should inform patients and their caregivers about the risk of adverse metabolic effects and educate them about the signs and symptoms of diabetes. Patients with risk factors for diabetes, who have a diagnosis of diabetes, or who are taking other medications associated with weight gain may benefit from aripiprazole or ziprasidone therapy, which cause less weight gain than other medications. The panel recommends that patients who develop worsening hyperglycemia or dyslipidemia during therapy be switched to a second-generation antipsychotic that has not been associated with significant weight gain or diabetes. The benefits of continuing effective psychiatric medications should be balanced with the patient's cardiovascular risk and the ability to achieve diabetes treatment goals.

The ADA's therapeutic goals for blood pressure, lipid levels, glycemic control, and monitoring in the general population also apply to patients with serious mental illness. However, patients with mental illness are less likely to receive recommended interventions.28,29 Although physicians should not alter therapeutic goals based only on the presence of a serious mental illness, they should prioritize therapy based on the patient's psychiatric status.

Cardiovascular Disease and QT Prolongation

Rates of cardiovascular and cerebrovascular diseases are higher in patients with schizophrenia compared with the general population.2 The calculated 10-year risk of coronary heart disease in patients with schizophrenia is 50 percent higher in women and 34 percent higher in men, compared with the general population. This increased risk may be partially caused by lifestyle factors; however, the metabolic effects of antipsychotic medications also may contribute.30 Physicians tend to treat risk factors for cardiovascular disease less aggressively in patients with diabetes who have serious mental illness compared with those who do not have mental illness.11

The use of antipsychotics, even at low doses, is associated with a threefold increase in the risk of cardiac sudden death in outpatients.31 QT prolongation is associated with ventricular arrhythmias, which can cause syncope, ventricular fibrillation, and sudden death.32 First- and second-generation antipsychotics have been associated with QT prolongation to varying degrees. The antipsychotic thioridazine (Mellaril; brand no longer available in the United States) has the greatest effect on the QT interval, followed by ziprasidone, haloperidol (Haldol), quetiapine, risperidone, and olanzapine.19 Aripiprazole has not been shown to cause QT prolongation.33

Medications known to cause QT prolongation (Table 434) should be avoided in patients with heart disease, history of syncope, family history of sudden death at any age, drug or alcohol abuse, personal or family history of congenital long QT syndrome, or electrolyte imbalances as well as in older women. For more information about medications associated with QT prolongation, go to http://www.arizonacert.org/medical-pros/drug-lists/drug-lists.cfm.

Table 4

Selected Medications Associated with QT Prolongation

Amiodarone (Cordarone)

Clarithromycin (Biaxin)

Digoxin

Disopyramide (Norpace)

Droperidol (Inapsine)

Erythromycin

Flecainide (Tambocor)

Fluoxetine (Prozac)

Gatifloxacin (Zymar)

Ibutilide (Corvert)

Methadone

Procainamide (Pronestyl)

Quinidine

Sotalol (Betapace)

Sparfloxacin (Zagam); no longer available in the United States

Tricyclic antidepressants


Information from reference 34.

Table 4   Selected Medications Associated with QT Prolongation

View Table

Table 4

Selected Medications Associated with QT Prolongation

Amiodarone (Cordarone)

Clarithromycin (Biaxin)

Digoxin

Disopyramide (Norpace)

Droperidol (Inapsine)

Erythromycin

Flecainide (Tambocor)

Fluoxetine (Prozac)

Gatifloxacin (Zymar)

Ibutilide (Corvert)

Methadone

Procainamide (Pronestyl)

Quinidine

Sotalol (Betapace)

Sparfloxacin (Zagam); no longer available in the United States

Tricyclic antidepressants


Information from reference 34.

Medications that can cause QT prolongation should not be prescribed concurrently. Medications that inhibit the metabolism of antipsychotic agents should be avoided, if possible. However, if these medications are prescribed, physicians should use caution because the effects on the QT interval appear to be related to increased serum drug concentrations.35

Performing baseline electrocardiography (ECG) before initiating antipsychotic therapy is controversial. However, ECG can identify patients with preexisting QT prolongation. Monitoring electrolyte and magnesium levels is suggested in patients receiving thioridazine or ziprasidone who are at risk of electrolyte deficiencies.36

Drug Interactions

Concurrent use of psychiatric medications and some medications commonly prescribed in primary care may lead to pharmacokinetic or pharmacodynamic interactions; therefore, when possible, primary care physicians should carefully consider risks and benefits when prescribing medications that may interact with psychiatric therapies. Pharmacokinetic interactions include those that cause changes in the metabolism of either agent. Pharmacodynamic interactions occur when two medications act at the same or related target sites, leading to additive, synergistic, or antagonistic effects.

Pharmacokinetic interactions often involve alterations in medication metabolism caused by the induction or inhibition of hepatic metabolism via the cytochrome P450 (CYP) enzyme system. Second-generation antipsychotics have varying effects on this enzyme system. Clozapine and olanzapine are primarily metabolized by the CYP1A2 system; risperidone, quetiapine, and ziprasidone by CYP3A4; and aripiprazole by CYP3A4 and CYP2D6.37  Medications that inhibit the metabolism of second-generation antipsychotics lead to higher drug levels and may cause toxicity or increased adverse effects. Interactions that induce the metabolism of second-generation antipsychotics may lead to lower drug levels, treatment failure, increased medication doses, and the potential for increased adverse effects when the interacting drug is discontinued. Table 5 presents selected pharmacokinetic interactions between second-generation antipsychotics and common agents.16,3743

Table 5

Selected Pharmacokinetic Interactions Between Second-Generation Antipsychotics and Common Agents

Second-generation antipsychotic Agents that lead to increased antipsychotic drug levels Agents that lead to decreased antipsychotic drug levels

Aripiprazole (Abilify)

Clarithromycin (Biaxin)*

Barbiturates

Erythromycin*

Carbamazepine (Tegretol)

Grapefruit juice*

Phenytoin (Dilantin)

Itraconazole (Sporanox)*

Ketoconazole (Nizoral)*

Quinidine*

Clozapine (Clozaril)

Caffeine

Barbiturates

Cimetidine (Tagamet)

Carbamazepine

Ciprofloxacin (Cipro)

Nicotine

Citalopram (Celexa)

Phenytoin

Erythromycin

Rifampin (Rifadin)

Fluoxetine (Prozac)

Fluvoxamine (Luvox)

Grapefruit juice

Paroxetine (Paxil)

Sertraline (Zoloft)

Olanzapine (Zyprexa)

Ciprofloxacin

Carbamazepine

Fluvoxamine

Nicotine

Omeprazole (Prilosec)

Phenytoin

Rifampin

Quetiapine (Seroquel)

Clarithromycin

Barbiturates

Erythromycin

Carbamazepine

Fluconazole (Diflucan)

Phenytoin

Grapefruit juice

Rifampin

Itraconazole

Theophylline

Ketoconazole

Risperidone (Risperdal)

Clozapine

Barbiturates

Fluoxetine

Carbamazepine

Paroxetine

Phenytoin

Rifampin

Ziprasidone (Geodon)

Clarithromycin

Carbamazepine

Erythromycin

Phenytoin

Fluconazole

Grapefruit juice

Itraconazole

Ketoconazole


*— Monitor for toxicity.

†— Decrease aripiprazole dose by one half.

References 16 and 37 through 43.

Table 5   Selected Pharmacokinetic Interactions Between Second-Generation Antipsychotics and Common Agents

View Table

Table 5

Selected Pharmacokinetic Interactions Between Second-Generation Antipsychotics and Common Agents

Second-generation antipsychotic Agents that lead to increased antipsychotic drug levels Agents that lead to decreased antipsychotic drug levels

Aripiprazole (Abilify)

Clarithromycin (Biaxin)*

Barbiturates

Erythromycin*

Carbamazepine (Tegretol)

Grapefruit juice*

Phenytoin (Dilantin)

Itraconazole (Sporanox)*

Ketoconazole (Nizoral)*

Quinidine*

Clozapine (Clozaril)

Caffeine

Barbiturates

Cimetidine (Tagamet)

Carbamazepine

Ciprofloxacin (Cipro)

Nicotine

Citalopram (Celexa)

Phenytoin

Erythromycin

Rifampin (Rifadin)

Fluoxetine (Prozac)

Fluvoxamine (Luvox)

Grapefruit juice

Paroxetine (Paxil)

Sertraline (Zoloft)

Olanzapine (Zyprexa)

Ciprofloxacin

Carbamazepine

Fluvoxamine

Nicotine

Omeprazole (Prilosec)

Phenytoin

Rifampin

Quetiapine (Seroquel)

Clarithromycin

Barbiturates

Erythromycin

Carbamazepine

Fluconazole (Diflucan)

Phenytoin

Grapefruit juice

Rifampin

Itraconazole

Theophylline

Ketoconazole

Risperidone (Risperdal)

Clozapine

Barbiturates

Fluoxetine

Carbamazepine

Paroxetine

Phenytoin

Rifampin

Ziprasidone (Geodon)

Clarithromycin

Carbamazepine

Erythromycin

Phenytoin

Fluconazole

Grapefruit juice

Itraconazole

Ketoconazole


*— Monitor for toxicity.

†— Decrease aripiprazole dose by one half.

References 16 and 37 through 43.

Family physicians should also be aware of pharmacodynamic interactions that may intensify the adverse effects of second-generation antipsychotics. As previously described, the concurrent use of medications that can cause QT prolongation, particularly with ziprasidone, can increase the risk of clinically significant QT prolongation and potentially increase the risk of torsades de pointes. Because of effects on alpha receptors, second-generation antipsychotics can cause orthostatic hypotension, which may intensify the effects of antihypertensive agents.

Alcohol and agents associated with central nervous system depression (e.g., sedatives, clonidine [Catapres], antihistamines, antiemetics) may have additive effects in patients using second-generation antipsychotics. Olanzapine, quetiapine, risperidone, and ziprasidone may antagonize the effects of levodopa and dopamine agonists, potentially decreasing the therapeutic benefit of the dopamine agents.

Clozapine should not be used with other agents that increase the risk of agranulocytosis or bone marrow suppression, including carbamazepine (Tegretol), ticlopidine (Ticlid), hydroxychloroquine (Plaquenil), and propylthiouracil. Clozapine can cause additive effects when administered with other drugs that have anticholinergic effects. Aripiprazole is the antipsychotic that binds most tightly to dopamine D2 receptors and has the potential to displace other first-and second-generation antipsychotics from their binding sites; this could lead to worsening disease symptoms when administered with other antipsychotics.38

Guidelines for Coordinating Patient Care

Fragmentation of care is a problem for many patients with serious mental illness, and several models address this issue.44,45 APA practice guidelines indicate that monitoring for metabolic effects of medications is the responsibility of the prescribing physician.46 Canadian guidelines recommend that psychiatrists perform screening tests for metabolic problems and refer patients to primary care physicians to follow up on abnormal test results.47 Responsibility for monitoring metabolic problems and vigilance for drug interactions and adverse reactions should be shared by all prescribers.

The Authors

BERNADETTE KIRALY, MD, is a clinical instructor in the Department of Family and Preventive Medicine at the University of Utah School of Medicine, Salt Lake City. She received her medical degree from Albany (NY) Medical College and completed a family medicine residency at the University of Utah School of Medicine.

KAREN GUNNING, PharmD, BCPS, is a clinical associate professor of pharmacotherapy in the College of Pharmacy and an adjunct associate professor in the Department of Family and Preventive Medicine at the University of Utah School of Medicine. She received her doctorate of pharmacy from the University of Utah College of Pharmacy, Salt Lake City, and completed a family medicine pharmacotherapy residency at the University of Washington School of Medicine, Seattle.

JENNIFER LEISER, MD, is a clinical assistant professor in the Department of Family and Preventive Medicine at the University of Utah School of Medicine. She received her medical degree at the University of Minnesota Medical School, Minneapolis, where she also completed a family medicine residency.

Address correspondence to Bernadette Kiraly, MD, Sugarhouse Family Health Center, 1138 Wilmington Ave., Salt Lake City, UT 84106 (e-mail: bernadette.kiraly@hsc.utah.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352(24):2515–2523.

2. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212–217.

3. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844–850.

4. Jones DR, Macias C, Barreira PJ, Fisher WH, Hargreaves WA, Harding CM. Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv. 2004;55(11):1250–1257.

5. Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry. 2005;66(2):167–173.

6. Druss BG, Rosenheck RA, Desai MM, Perlin JB. Quality of preventive medical care for patients with mental disorders. Med Care. 2002;40(2):129–136.

7. Desai MM, Rosenheck RA, Druss BG, Perlin JB. Mental disorders and quality of diabetes care in the veterans health administration. Am J Psychiatry. 2002;159(9):1584–1590.

8. Druss BG, Rosenheck RA. Mental disorders and access to medical care in the United States. Am J Psychiatry. 1998;155(12):1775–1777.

9. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA. 2000;283(4):506–511.

10. Graber MA, Bergus G, Dawson JD, Wood GB, Levy BT, Levin I. Effect of a patient's psychiatric history on physicians' estimation of probability of disease. J Gen Intern Med. 2000;15(3):204–206.

11. Kreyenbuhl J, Dickerson FB, Medoff DR, et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis. 2006;194(6):404–410.

12. Levinson Miller C, Druss BG, Dombrowski EA, Rosen-heck RA. Barriers to primary medical care among patients at a community mental health center. Psychiatr Serv. 2003;54(8):1158–1160.

13. Daumit GL, Goldberg RW, Anthony C, et al. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis. 2005;193(10):641–646.

14. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284(20):2606–2610.

15. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183–194.

16. Abilify (aripiprazole) [package insert]. Princeton, N.J.: Bristol-Meyers Squibb; 2008. http://packageinserts.bms.com/pi/pi_abilify.pdf. Accessed June 22, 2007.

17. Taylor DM, McAskill R. Atypical antipsychotics and weight gain—a systematic review. Acta Psychiatr Scand. 2000;101(6):416–432.

18. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–1696.

19. Masand PS, Fazal FS, Patkar AA. Safety considerations in pharmacotherapy of bipolar disorder. CNS Spectr. 2004;9(11 suppl 12):16–26.

20. Lambert TJ, Chapman LH, for the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust. 2004;181(10):544–548.

21. Cohen D, Stolk RP, Grobbee DE, Gispende Wied CC. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care. 2006;29(4):786–791.

22. Basu A, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophr Res. 2006;86(1–3):99–109.

23. Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy. 2007;27(1):27–35.

24. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.

25. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51(8):480–491.

26. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(suppl 18):27–35.

27. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006;163(10):1821–1825.

28. Jones LE, Clarke W, Carney CP. Receipt of diabetes services by insured adults with and without claims for mental disorders. Med Care. 2004;42(12):1167–1175.

29. Dixon LB, Kreyenbuhl JA, Dickerson FB, et al. A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses [published correction appears in Psychiatr Serv. 2004;55(9):1005]. Psychiatr Serv. 2004;55(8):892–900.

30. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45–53.

31. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death [published correction appears in Arch Intern Med. 2004; 164(17):1839]. Arch Intern Med. 2004;164(12):1293–1297.

32. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334–1349.

33. Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Saf. 2005;28(1):35–51.

34. Center for Education and Research on Therapeutics. Drugs that prolong the QT interval and/or induce torsades de pointes ventricular arrhythmia. http://www.arizonacert.org/medical-pros/drug-lists/drug-lists.cfm. Accessed June 21, 2007.

35. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58(12):1161–1167.

36. Vieweg WV. Strategies to prevent fatal arrhythmias in patients taking antipsychotics. Current Psychiatry. 2002;1(5):10–21.

37. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003;28(2):99–112.

38. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics. 2005;46(5):464–494.

39. Zyprexa (olanzapine) [package insert]. Indianapolis, Ind.: Eli Lilly and Company; 2007. http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed June 21, 2007.

40. Geodon (ziprasidone) [package insert]. New York, NY: Pfizer; 2007. http://www.pfizer.com/pfizer/download/uspi_geodon.pdf. Accessed June 21, 2007.

41. Seroquel (quetiapine fumarate) [package insert]. Wilmington, Del.: Astra Zeneca; 2007. http://www.astrazeneca-us.com/pi/seroquel.pdf. Accessed June 22, 2007.

42. Clozaril (clozapine) [package insert]. East Hanover, N.J.: Novartis; 2005. http://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf. Accessed June 21, 2007.

43. Risperdal (risperidone) [package insert]. Titusville, N.J.: Janssen;2008.http://www.janssen.com/janssen/shared/pi/risperdalconsta.pdf. Accessed June 22, 2007.

44. Druss BG, Rohrbaugh RM, Levinson CM, Rosenheck RA. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry. 2001;58(9):861–868.

45. Golomb BA, Pyne JM, Wright B, Jaworski B, Lohr JB, Bozzette SA. The role of psychiatrists in primary care of patients with severe mesntal illness. Psychiatr Serv. 2000;51(6):766–773.

46. Lehman AF, Lieberman JA, Dixon LB, et al., for the American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 suppl):1–56.

47. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry. 2006;51(8):492–501.



Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article